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Abstract 
Biosimilar drugs must closely resemble the pharmacological attributes of innovator products to 
ensure safetyand efficacy to obtain regulatory approval. Glycosylation is one critical quality attribute 
that must be matched, but it is inherently difficult to control due to the complexity of its biogenesis. 
This usually implies that costly and time-consuming experimentation is required for clone 
identification and optimization of biosimilar glycosylation. Here, we describe a computational method 
that utilizes a Markov model of glycosylation to predict optimal glycoengineering strategies to obtain a 
specific glycosylation profile with desired properties. The approach uses a genetic algorithm to find 
the required quantities to perturb glycosylation reaction rates that lead to the best possible match 
with a given glycosylation profile. Furthermore, the approach can be used to identify cell lines and 
clones that will require minimal intervention while achieving a glycoprofile that is most similar to the 
desired profile. Thus, this approach can facilitate biosimilar design by providing computational 
glycoengineering guidelines that can be generated with a minimal time and cost. 
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1 Introduction 
During biosimilar development, process parameters are adjusted to reproduce the pharmacological 
and biochemical properties of the original approved innovator protein drug. Protein glycosylation is a 
critical post-translational modification on most secreted mammalian proteins, and variations in glycan 
structure can significantly impact the bioactivity of a protein (Dalziel et al., 2014; Griebenow and Sola, 
2009; Jefferis, 2009; Li and d’Anjou, 2009; Raju, 2008; Solá and Griebenow, 2011). Thus, regulatory 
agencies require that biosimilar drug glycoforms match the approved drug. Consequently, engineering 
the glycoprofile, i.e. the relative frequencies of glycans present on the protein, is a critical part of 
biosimilar production (Chiang et al., 2016; Niwa and Satoh, 2015; Tsuruta et al., 2015; Zhang et al., 
2016). 
 
Reproducing a glycoprofile can be difficult since, in theory, a cell could synthesize thousands of 
different glycans. Protein glycosylation is a non-template driven process whose outcome follows a 
statistical distribution. It is often difficult to predict this process with pure intuitive reasoning since 
perturbation of a glycosyltransferase will affect the abundances of glycans and the rates of other 
reactions connected to it, often leading to non-obvious glycoforms. As a consequence, expansive 
profiling of diverse clones and elaborate titration experiments are usually necessary. Therefore, 
computer simulations could provide valuable guidance by predicting the required quantities of 
reaction rate perturbation or aid in clone selection to facilitate glycoengineering efforts.  
 
We previously developed a model of glycosylation that captured the stochastic nature of its biogenesis 
by conceptualizing it as a Markov chain process (Spahn et al., 2016). The advantage of this 
probabilistic approach is that the many factors influencing the kinetics of glycosylation reactions are 
subsumed in probabilities, thus avoiding the necessity to estimate kinetic parameters. Instead, the 
model uses an initial known glycoprofile from a starting production cell line. The observed glycan 
frequencies in this profile are used to empirically reconstruct the probabilities for each glycosylation 
reaction in the network. After this fitting process, the model can simulate how the glycoprofile will 
change after perturbing one or more enzyme-dependent reaction sets (see Methods) . These 
perturbations can include various experimental techniques that can either involve cell engineering 
(knock-downs or overexpression of glycosylation genes) or bioprocess control (media 
supplementation with nutrients or inhibitors). Although this and other glycosylation models (Spahn 
and Lewis, 2014; Villiger et al., 2016) allow one to make a priori predictions of glycoprofiles, there is 
still a great need for easy-to-use computational approaches that would directly address 
glycoengineering efforts and help to quantitatively predict optimal perturbation strategies to 
recapitulate a desired glycoprofile.  
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Here we present a novel optimization-based implementation of the glycosylation Markov model that 
predicts the quantitative amount by which glycosylation reaction rates must be perturbed to achieve a 
desired glycoprofile. We demonstrate how this approach can guide glycoengineering in the context of 
biosimilar production, where the desired glycoprofile is already known, but the quantitative 
perturbations necessary to achieve it are not. To accomplish this, we reverse the simulation workflow 
such that, rather than predicting an unknown glycoprofile, the simulation predicts the optimal level of 
reaction rate perturbation that achieves a glycoprofile. We demonstrate the capabilities of this 
approach to predict experimental interventions needed to mimic the glycoprofile of Rituximab and 
Erythropoietin (EPO). These model-derived predictions can then serve as guidance to efficiently adjust 
the experimental means (e.g. the concentration range of an inhibitor). In addition, these simulations 
can help to assess which glycoprofiles will be harder or easier to engineer towards desired properties. 
This can help identify production cell lines that produce proteins with glycosylation profiles that will 
require minimal experimental modification to match the innovator drug. 
 
 
2 Materials and methods 
2.1 Glycoprofiling 
Glycoprofiling was performed as previously published (Grav et al., 2015). Exponentially growing cells 
were seeded at 1x106 cells/mL and supernatant was harvested after 4 days by centrifugation. 
Supernatant for all samples was filtered before further processing. Rituximab was purified using 
HiTrap MabSelect columns (GE Healthcare) according to the manufacturer’s instructions. EPO 
containing supernatants (175 mL) were buffer exchanged with 400 mL 20 mM TRIS-HCl pH 8.0 using a 
VivaFlow 50 30 kDa MWCO cross flow cassette (Sartorius). Samples were loaded onto a Mono Q 5/50 
GL column (GE Healthcare) and EPO was eluted using a gradient increase to 20 mM TRIS-HCl pH 8.0, 
300 mM NaCl over 30 column volumes. EPO containing fractions were pooled and analyzed by SDS 
PAGE. Concentrations of Rituximab and EPO were measured by Nanodrop (Thermo Scientific). N-
glycans from purified proteins were released and fluorescently labeled with GlykoPrep Rapid N-
Glycan kit (ProZyme Inc., Hayward, CA). Labeled N-glycans were analyzed by LC-MS on a Thermo 
Ultimate 3000 HPLC with fluorescence detector coupled on-line to a Thermo Velos Pro Iontrap MS. 
Glycan abundance was measured by integrating the areas under normalized fluorescence spectrum 
peaks with Xcalibur software (Thermo Fisher Scientific) giving the relative amount of the glycans. 
 
2.2 Simulation 
The Markov model of glycosylation, including the rationale to computationally predict perturbations, 
is implemented as previously published (Spahn et al., 2016). Based on the data given in the initial 
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glycoprofile, reaction probabilities are reconstructed to generate the model for the glycosylation 
reaction network present in the cell line from which the initial glycoprofile was obtained. An objective 
function is defined that takes this initial model, a list of perturbations of it, and the provided target 
profile as input variables. A perturbation is defined as the name of a glycosylation enzyme and a 
quantity q by which its reaction set is to be scaled up (if q > 1) or down (if 0 < q < 1). The term 
“reaction set” refers to the entirety of reactions in the glycosylation reaction network that depend 
upon a specific glycosylation enzyme. The objective function returns the mismatch between the 
computed perturbed profile and the target profile. To find a minimum of this mismatch, a genetic 
algorithm, as implemented in MATLAB (function ga), is set up that infers the optimal quantity of 
perturbation over the space of all possible quantities of perturbation within a given range between 0 
and a maximum upper bound (qmax = 10 used in this study). Specifying this upper bound is also helpful 
in situations where it is clear that certain reaction sets need to be scaled down rather than up in which 
case the upper bound can be set to 1. The stopping criterion is set to a maximum of 20+(Number of 
reaction sets)*20 generations while premature stopping occurs if the best objective function value 
stalls for more than 10 generations. Population size is set to 20 individuals with default settings for 
selection, crossover and mutation. Refer to standard literature (e.g. (Mitchell, 1998) as well as the 
MATLAB website (www.mathworks.com) for an explanation of genetic algorithm rationale and 
terminology. Mismatch between two profiles is calculated as the absolute distance between average 
glycan frequencies, summed over all glycans in the profiles. Individual (non-negative) weights can be 
defined for individual glycans to adjust their impact on the overall mismatch between two profiles. If 
all weights are set to 1 (as used throughout this paper), the metric equals the Manhattan metric. A 
least 10 independent runs of the genetic algorithm were evaluated for each glycoprofile that all 
yielded the same minimal possible profile mismatch. In order to assess robustness, the predicted 
optimal quantities of perturbation were allowed to randomly vary by 10% and the resulting 
glycoprofiles were recalculated. 
 
 
3 Results  
3.1 An application of the glycosylation Markov model predicts how to achieve a target 
glycoprofile 
The Markov model provides a platform to predict changes in an initial glycoprofile (i.e. the profile 
obtained from the production cell line as it stands) following reaction rate perturbations (Spahn et al., 
2016). To predict the optimal engineering strategy to achieve a desired glycoprofile, here we reverse 
the workflow such that, in addition to the initial glycoprofile, the target glycoprofile (i.e. the desired 
profile of the innovator product) needs to be provided. In addition, it can be specified which enzyme-
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dependent glycosylation reaction sets are supposed to be perturbed. This choice is optional, but since 
often not all glycosylation reactions require perturbation, or only a subset is amenable to perturbation 
with the experimental means at hand, specification will speed up computation. For example, if a 
chemical inhibitor of a fucose transporter is to be used in combination with a supplementation of UDP-
galactose, FucT and GalT would be specified as glycosylation reaction sets since fucosylation and 
galactosylation reactions are being affected through these treatments. 
 
The simulation starts by first fitting the Markov model to the initial glycoprofile to infer the reaction 
probabilities in the production cell line (Spahn et al., 2016). To find an optimal quantitative strategy to 
engineer this profile towards the target profile, the simulation runs a genetic algorithm that randomly 
modifies the levels of perturbation in the specified reaction set, computes the resulting changes in the 
glycoprofile and retains the best solutions. By mixing and randomly changing these solutions, the 
algorithm iteratively converges on the target profile and reaches an optimal level of perturbation (see 
Methods). The final quantitative levels of perturbations leading to this optimum are returned. The 
similarity between glycoprofiles is measured by using a profile mismatch metric. This metric can be 
flexibly defined for the requirements of the specific glycoengineering problem. For example, if certain 
glycans are more important than others in the profile (due to regulatory or functional reasons), 
weights can be assigned to them so these priorities are reflected by the simulation (see Methods). 
 
3.2 Engineering strategies can be designed to match the glycoprofile of IgGs 
We demonstrate the workflow with Rituxmab, a monoclonal antibody of high commercial interest 
(Daniel et al., 2015; Turner, 2015; Visser et al., 2013). The glycoprofile of the innovator drug shows the 
typical pattern of an IgG1 antibody featuring G0, G1 and G2 glycoforms as well as a low level of 
fucosylation (Visser et al., 2013) (Fig. 1A). Achieving this glycoprofile usually requires a considerable 
degree of glycoengineering since CHO cell lines used for production typically display profiles that 
show higher degrees of fucosylation. When produced in a CHO-S line, the Rituximab glycoprofile has 
all glycoforms being fucosylated (Fig. 1A). Since the target profile on the innovator drug shows only 
minor fractions of fucosylation, the FucT reaction set is an obvious target for downregulation through 
glycoengineering, but due to the intertwined nature of the glycosylation reaction network (Fig. 1E) the 
magnitude of downregulation of FucT activity is non-obvious. Running the Markov-model based 
simulation, a downregulation to ~2% is predicted to give the closest possible match to the desired 
target profile, if only fucosylation is allowed to be altered (Fig. 1B). However, as evident from the 
frequency mismatches in the predicted profile (glycans G0-G2), the increased levels of galactosylated 
glycoforms present on the innovator profile require further modification, so it is reasonable to alter 
the GalT reaction set as well. By allowing perturbation of both reaction sets, an optimal perturbation 
that matches the degree of both galactosylation and fucosylation is computed to be at 41% 
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upregulation of the GalT reaction set and downregulation to ~2% of the FucT reaction set (Fig. 1C). As 
mentioned above, custom weights could be applied for individual glycans, e.g. if a match in G1 (rather 
than G0) is to be given higher priority because stability concerns are not an issue (Raju and Scallon, 
2007). Finally, the target profile also includes a fraction of high-mannose glycoforms, so GnTI can be 
added to the list of reaction sets to be altered because failure to add the respective GlcNAc at this point 
in the network will cause secretion of unprocessed (high-mannose) glycoforms. As predicted by the 
simulation, an excellent match to the target profile can be obtained by reducing GnTI to ~98% while 
increasing galactosylation by ~30% and decreasing fucosylation to ~2% since also the M5 fraction 
will be successfully reproduced (Fig. 1D, arrow). Thus, our model-based simulation can give helpful 
clues into how close a certain target profile can be matched with a given initial cell line, and also 
provides the predicted reaction rate perturbations that will transform the initial profile accordingly. 
 
3.3 Validation based on glycosyltransferase knock-out cell lines 
In order to validate that our simulation framework can infer perturbations based on glycoprofiles, we 
tested it on glycosyltransferase knock-out cell lines in CHO, published previously (Yang et al., 2015). A 
starting glycoprofile was obtained for EPO, expressed in a wildtype CHO-GS cell line. The model was 
used to predict the modifications required to match target profiles for mgat4A/4B, mgat5 and 
mgat4A/4B/5 knock-out cell lines, and the simulation correctly inferred the complete abrogation of 
GnTIV, GnTV and GnTIV + GnTV, respectively (Fig. 2A, 1-3). Interestingly, a slight perturbation to 
GnTIV was also seen for the GnTV knock-out, suggesting that those reactions were also moderately 
affected. However, the results here demonstrated that even for more complex multi-gene strategies, 
the model can accurately predict the strategy to perturb glycosylation to achieve a desired 
glycoprofile.  
 
3.4 Clones can be screened to test feasibility of engineering strategies 
The approach presented here allows one to predict how to engineer a cell line to obtain glycoprofiles 
that approximate a desired innovator drug profile. However, different cell lines typically produce 
glycoprofiles that differ in their consistency with the target profile. Thus, it can be difficult to select the 
best cell line for glycoengineering efforts because it could be unclear which one requires less complex 
genetic or processing-related adjustments. Furthermore, it is often unclear which cell lines can be 
brought closest to the target profile. Our approach could therefore be valuable in choosing an optimal 
production line as it can give a quick guidance into the complexity of engineering strategies and assess 
the degree of match achievable for each cell line. We exemplify this application with two glycoprofiles 
on EPO produced in CHO lines, and compare the optimal strategies to achieve a profile from the 
literature (Yang et al., 2015). As shown by the simulation, both cell lines can approach the target 
profile through perturbation of SiaT, GnTIV and GnTV-dependent reactions. However, cell line #1 
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attains a considerably better match after glycoengineering, despite having an initial glycoprofile that 
differs more substantially from the innovator drug than cell line #2 (Fig. 2B). Indeed, the simulation 
indicates that even an optimal glycoengineering strategy can only obtain a mediocre match to the 
target profile for cell line # 2 (Fig. 2B). Consequently, the optimal cell line for glycoengineering is not 
necessarily the one showing the best initial match to the target profile. Computational analyses like 
these could be carried out even on a large collection of cell line candidates and help in prioritization 
and proper selection of glycoengineering methods. 
 
4 Discussion  
Here we have presented a novel approach that allows the prediction of engineering strategies to 
obtain a target glycoprofile, such as a profile from an innovator drug. It is important to note that the 
strategies predicted by our model represent quantities by which glycosylation reaction rates need to 
be perturbed. As such, our model makes no restriction on how these perturbations could be carried 
out experimentally. In fact, finding the right experimental tool for implementing these predicted 
quantitative perturbations is a challenge to the cell engineer; fortunately, recent progress in genetic 
and metabolic cell culture engineering have made a wide range of options available in this field the 
choice of which will largely depend on the specific perturbation to be obtained (Brühlman et al., 2015).  
 
For example, if the model suggests a reduction in reaction rates, small-interfering RNA represents an 
inexpensive and effective option since downregulation of glycosylation genes can effectively change 
the glycoprofile (Imai-Nishiya et al., 2007). Alternatively, small molecules, such as sugar analogs or 
chemical inhibitors, can be used to reduce the rates of certain glycosylation reactions (Gardai et al., 
2015; Okeley et al., 2013; Pande et al., 2015; Rillahan et al., 2012; Surve and Gadgil, 2015); also, the 
reduction of glucose has been reported as a way to reduce galactosylation levels (Villacres et al., 
2015). Future work will aim to link to various media and bioprocesses treatments to other enzymatic 
reactions, thus further expanding the means by which such interventions can be used in a predictable 
manner. Since these non-genetic methods only require modification of the growth medium, they 
would be preferable in cases where manipulation of the cell line in use is not desired. Since the 
compounds used (siRNA or small molecules, respectively) can be titrated, these methods are 
particularly attractive for partial reduction of reaction rates where the quantitative level of reaction 
activity is supposed to match the level predicted by the model. In contrast, if total abrogation (i.e. a 
reduction to nearly 0%) is indicated by the model, genetic knock-outs of one or more glycosylation 
genes through zinc-finger nucleases, TALENS or CRISPR-Cas9 technology (Gaj et al., 2013; Kim and 
Kim, 2014; Lee et al., 2015) may be more attractive options since these methods provide a more 
effective way to permanently eliminate gene activity.  
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In cases where the model suggests increases in glycosylation reaction rates (see Fig. 2B), both genetic 
and metabolic perturbation strategies could be employed as well. Genetic approaches would, for 
example, include ectopic expression of glycosyltransferases or CRISPR-mediated gene activation in 
order to increase certain glycosylation reaction rates (Lin et al., 2015; Perez-Pinera et al., 2013; 
Weikert et al., 1999; Zalatan et al., 2015). Such ectopic expression could be combined with inducible 
promoters (Gossen and Bujard, 1992; Weber et al., 2004) to quantitatively control the increase of 
transgene expression, and thus reaction rates. Alternatively, supplementation of the growth medium 
with sugars, sugar-nucleotides or cofactors (e.g. manganese) provides a powerful method to increase 
certain glycosylation reactions as exemplified in several studies (Grainger and James, 2013; Gramer et 
al., 2011; St Amand et al., 2014). In addition to modifications of either the growth media or the host 
genome or transcriptome, protein yield can be another cell culture parameter affecting the 
glycoprofile. For instance, increases in protein yield can indirectly downregulate glycosylation 
reactionrates since under high protein production sugar substrates can become limiting. Also, at high 
protein production rates, glycosylation enzymes might not be capable of processing the entire bulk of 
Golgi-transiting proteins, thus leaving a higher fraction to remain in their unmodified, high-mannose 
glycoform (del Val et al., 2016).  
 
Thus, multiple different approaches could be taken to fine-tune the activity of specific biosynthetic 
reactions in glycosylation. However, the ease of supplementing media with either inhibitory or 
stimulating agents makes it the most convenient strategy for implementing the model-predicted 
down- or upregulations, respectively. Genetic knock-outs might be the preferred method if a reaction 
set needs to be shut down completely and if genetic engineering of the production cell line is an 
option. 
 
As demonstrated by the increasing profile similarity (Fig. 1 B-D), inclusion of multiple reaction sets for 
perturbation should typically obtain a closer match to the target profile, but it also increases 
complexity of the optimization problem resulting in slower convergence (i.e. increased computation 
time). More practically, however, the inclusion of more enzymes will require more complex 
experiments to fine-tune the engineering strategies. Also, glycosylation reactions are not perfectly 
independent since they all rely upon a shared sugar nucleotide metabolic network. Future advanced 
models could take this into account by integrating sugar metabolism into the prediction of glycoforms, 
as already demonstrated for kinetic glycosylation models (Jedrzejewski et al., 2014; Villiger et al., 
2016). Thus, efforts that employ the simplest strategy resulting in a glycoprofile that meets 
requirements of safety, efficacy, and similarity are preferred.  
 
In summary, while this approach contributes to a growing body of work on modeling glycosylation 
with a variety of computational methods (Hossler, 2012; Neelamegham and Liu, 2011; Spahn and 
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Lewis, 2014), our method is the first that directly addresses model-based prediction of biosimilar 
design. The probabilistic foundation of it makes it especially valuable for rapid in silico screens as 
running the simulation requires no input other than the initial and the target glycoprofiles and the 
specification of the reaction sets to be perturbed. The method is fully flexible and can be used for any 
cell line and any recombinant glycoprotein. It can, thus, be a helpful asset in QbD-oriented 
glycoengineering efforts. 
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Figure legends 
 
 
Figure 1. (A): Glycoprofiles on Rituximab, expressed in CHO-S cell line before any glycoengineering 
(“Initial”). The target profile shows the glycoprofile of the innovator drug as reported previously 
(Visser et al., 2013). (B)-(D): Results from the Markov-model based glycoengineering simulation (two 
representative runs shown) considering only FucT (B), FucT+GalT (C) or FucT+GalT+GnTI (D) 
reaction sets for perturbation. Profile mismatch evolution plots (left) show the worst, best and mean 
profile mismatches in each generation of the genetic algorithm. Perturbation plots (right) show the 
quantity of predicted perturbation yielding the best match in each generation. Glycoprofiles (far right) 
are calculated with the averages of perturbations throughout all independent simulation runs. Error 
bars are standard deviation. (E): Reaction network for the glycoprofiles on Rituximab and partial 
reaction network reconstructed for the glycoprofile on erythropoietin. Reactions are color-coded 
according to the glycosylation enzyme involved. 
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Figure 2. (A): Glycoprofiles on EPO, expressed in CHO-GS (Wildtype and knock-out data from (Yang et 
al., 2015)). The simulation infers the required perturbations in SiaT, GnTIV and GnTV that transform 
the wildtype profile into the observed knock-out profiles (one representative run shown). Error bars 
are standard deviation. (B): Glycoengineering of two EPO-producing CHO lines with varying degrees 
of branching and sialylation. The reaction sets dependent on the branching enzymes GnTIV & GnTV 
and sialyltransferase (SiaT) are subject to perturbation in simulations (one representative run 
shown).Glycoprofiles are calculated with the averages of perturbations throughout all independent 
simulation runs. Error bars are standard deviation. Brackets indicate the range of the predicted 
averages when optimal predicted perturbations are varied by 10% (Methods). 
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